Journal
ANNUAL REVIEW OF MEDICINE, VOL 70
Volume 70, Issue -, Pages 105-120Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-040717-051150
Keywords
tuberculosis; latent tuberculosis infection; dose optimization; drug resistance
Categories
Funding
- FIC NIH HHS [R25 TW009340] Funding Source: Medline
- NIAID NIH HHS [K23 AI135102, R01 AI111992] Funding Source: Medline
- NICHD NIH HHS [R01 HD074944] Funding Source: Medline
- FDA HHS [R01 FD004794] Funding Source: Medline
Ask authors/readers for more resources
Tuberculosis (TB) is one of the oldest infections afflicting humans yet remains the number one infectious disease killer worldwide. Despite decades of experience treating this disease, TB regimens require months of multidrug therapy, even for latent infections. There have been important recent advances in treatment options across the spectrum of TB, from latent infection to extensively drug-resistant (XDR) TB disease. In addition, new, potent drugs are emerging out of the development pipeline and are being tested in novel regimens in multiple currently enrolling trials. Shorter, safer regimens for many forms of TB are now available or are in our near-term vision. We review recent advances in TB therapeutics and provide an overview of the upcoming clinical trials landscape that will help define the future of worldwide TB treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available